Wall Street took a separate view, but Arca Biopharma Inc. CEO Michael Bristow said he is "very pleased with the outcome of this trial," a phase IIb experiment testing beta blocker and mild vasodilator Gencaro (bucindolol hydrochloride) compared with Toprol XL (metoprolol succinate, Astrazeneca plc).